Cancer deaths rose to 10 million and new cases jumped to over 23 million globally in 2019, according to a new study from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School of Medicine published in JAMA Oncology. At the start of the decade in 2010, total cancer deaths numbered 8.29 million worldwide and new cancer cases were at 18.7 million; the counts by the end of the decade in 2019 represent increases of 20.9% and 26.3%, respectively.
The paper is part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019), the largest and most comprehensive effort to quantify health loss across places and over time. Led by IHME, it draws on the work of more than 7,000 collaborators from more than 156 countries and territories.
Study Methods and Findings
The researchers estimated cancer burden and trends globally for 204 countries and territories. They found that cancer was second behind only cardiovascular diseases in the number of deaths, disability-adjusted life years (DALYs), and years of life lost (YLLs) among 22 groups of diseases and injuries globally in 2019. Within the total cancer burden, the five leading causes of cancer-related DALYs for both sexes combined were tracheal, bronchus, and lung cancer; colon and rectal cancer; stomach cancer; breast cancer; and liver cancer. Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths in 119 countries and territories for men and 27 countries and territories for women.
Although the absolute burden of cancer increased in both deaths and new cases from 2010 to 2019, the global age-standardized mortality and incidence rates decreased by 5.9% and 1.1%, respectively. From a country perspective, the age-standardized mortality rate decreased in 131 countries and territories and the age-standardized incidence rate lessened in 75 countries and territories.
The small percentage declines globally are promising, but the researchers cautioned that there may be setbacks in cancer care and outcomes due to COVID-19. The effects of the pandemic on cancer morbidity, mortality, and prevention and control efforts were not accounted for in this GBD study, which analyzed global cancer burden through 2019.
The authors also analyzed cancer burden based on socio-demographic index (SDI), a composite measure of income per capita, average years of education, and total fertility rate for people younger than age 25 years. While the global trend for age-standardized mortality and incidence rates is encouraging, the reduction in rates appears to be driven by higher SDI locations. For mortality, age-standardized rates decreased in the middle, middle-high, and high quintiles, and increased in the low and low-middle quintiles. Similarly, for incidence, the age-standardized rates decreased in the high-middle and high quintiles—with the largest decrease in the high SDI quintile—while increasing in the low, low-middle, and middle SDI quintiles.
“Ensuring that global progress against cancer burden is equitable is crucial,” said Jonathan Kocarnik, MPH, PhD, lead author of the study and a research scientist at IHME. “This will require efforts to reduce disparities in cancer prevention, treatment, and survival, and the incorporation of local needs and knowledge into tailored national cancer control plans.”
Dr. Kocarnik and his coauthors suggested that the larger increases in the lower SDI quintiles likely reflect ongoing epidemiologic transitions, demographic shifts, and disparities in cancer prevention, care, and control. Even without accounting for the COVID-19 pandemic, the absolute burden of cancer is already growing substantially worldwide.
Some additional findings from the study:
The study authors concluded, “The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.”
Disclosure: For full disclosures of the study authors, visit jamanetwork.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.